NCT00167583View on ClinicalTrials.gov

Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB)

PHASE3CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Behcet's DiseasePanuveitisPosterior UveitisRetinal Vasculitis
Interventions
DRUG

Cyclosporin A

3 mg/kg bw, augmented to 5 mg if necessary and combined with prednisolone. Adapted to serum levels

DRUG

Interferon-alpha2a

3-6 million iU per day sc., augmented to up to 9 if necessary, later reduced (according to clinical response) to 3 x 3 million iU /week.

Trial Locations (1)

D-72076

Department of Internal Medicine II and Department of Ophthalmology, Tübingen

All Listed Sponsors
lead

University Hospital Tuebingen

OTHER

NCT00167583 - Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB) | Biotech Hunter | Biotech Hunter